Ischemic stroke and retinal artery occlusion after carotid aneurysm embolization.

We present the case of a 72-year-old male with a right carotid aneurysm incidentally discovered after an ischemic stroke. After management of the stroke, stent-assisted coil embolization was performed to treat the aneurysm. Two simultaneous and early complications occurred: new ischemic strokes and branch retinal artery occlusions, respectively in the right occipital lobe and in the right eye. Treatment of unruptured carotid aneurysm using stent-assisted coil embolization can lead to severe complications involving both the brain and the retina. Multidisciplinary and close surveillance of patients should be performed to diagnose adverse effects of this endovascular treatment.

Assessment of Spontaneous Retinal Arterial Pulsations in Acute Central Retinal Vein Occlusions.

Central retinal vein occlusion (CRVO) is a common retinal disease. Recent works mentioned spontaneous retinal arterial pulsations (SRAPs) as a feature of some CRVOs. This is a retrospective study on patients presenting with CRVO who were followed up for at least 6 months. The objective was to identify SRAP in the acute phase of the disease and determine their relationship with patients' characteristics and visual prognosis. A 10-second infrared film centered on the optic disc was recorded within a month of the onset of symptoms, and SRAPs were detected in two-thirds of the cases. Patients with SRAP were significantly younger than those without SRAP. Mean central macular thickness was significantly higher in the absence of SRAP, which was translated into a more severe macular edema; however, this difference faded with time. BCVA tended to be higher in the presence of SRAP at the 6-month follow-up when adjusted to baseline. This study demonstrates that SRAPs are a frequent finding, easily detected by infrared fundus video recording, and associated with a younger age and lesser macular edema.

Incidence and Risk Factors of Ocular Hypertension following Pars Plana Vitrectomy and Silicone Oil Injection.

PURPOSE: To evaluate the risk factors for elevated intraocular pressure (IOP) after pars plana vitrectomy (PPV) with silicone oil injection (SOI). PROCEDURES: This prospective interventional study included 254 consecutive eyes receiving PPV with SOI. RESULTS: Elevated IOP developed in 48% of the eyes postoperatively. The onset of IOP elevation was early (≤1 week) in 61.5% of the eyes, intermediate (1-6 weeks) in 28.7%, and late (> 6 weeks) in 9.8%. The incidence of IOP elevation was higher with primary uncomplicated rhegmatogenous retinal detachment than with tractional detachment (p = 0.01). Pseudophakia, high myopia, and high preoperative IOP were found to have higher incidences of ocular hypertension, whereas diabetic patients had a lower incidence. CONCLUSION: IOP elevation is a common complication following silicone oil (SO) tamponade. Risk factors for ocular hypertension development are pseudophakia, high myopia, high preoperative IOP, and low-viscosity SO.

VITREORETINAL SURGERY WITH SILICONE OIL TAMPONADE IN PRIMARY UNCOMPLICATED RHEGMATOGENOUS RETINAL DETACHMENT: Clinical Outcomes and Complications.

BACKGROUND: To determine the anatomical and functional outcomes and possible complications after pars plana vitrectomy (PPV) with silicone oil (SO) tamponade in primary uncomplicated rhegmatogenous retinal detachments. METHODS: This is a prospective observational study. Overall, 62 consecutive patients who underwent surgical repair by PPV and SO injection for primary uncomplicated rhegmatogenous retinal detachment between January 01, 2006 and April 30, 2012 were followed. In general, PPV was chosen over scleral buckling when a significant cataract or a vitreous hemorrhage prevented adequate fundus visualization. Silicone oil was chosen over gas tamponade in patients living at 1,000 meters above the sea level, where SF6 or C3F8 tamponade could not be performed because of the risk of acute increase of intraocular pressure (IOP). One thousand centistokes SO was used in all eyes. At all visits, patients had a detailed ocular history and thorough bilateral evaluation, including best-corrected visual acuity, anterior segment examination, and IOP measurements by aplanation and fundus examination. Outcomes were assessed at 1 day, 1 week, 1 month, 3 months, 6 months, and every 6 months thereafter. Increased IOP was defined as an IOP of more than 21 mmHg. RESULTS: Anatomical success rate, final best-corrected visual acuity, IOP elevation, cataract formation, and other complications were the main outcome measures. This study included 62 eyes of 62 patients (41 men and 21 women) that underwent retinal detachment repair by PPV and SO injection. The age at the time of intervention was 57.6 ± 10.5 years (mean ± standard deviation; range, 34-79 years). All patients were whites. Mean follow-up was 24.5 ± 17.3 months (range, 6-70 months). Anatomical success rate defined as retinal reattachment 6 months after SO removal was 93.5%. Final BCVA was improved in 55 eyes (88.7%), with a mean of 4 Snellen lines, unchanged in 5 (8.1%), and worse in 2 eyes (3.2%), with a mean of 3 Snellen lines. Mean duration of SO tamponade was 5.12 ± 2.37 months (range, 2-12 months). From the 30 eyes that were still phakic after vitrectomy, 24 eyes (80.0%) underwent cataract surgery within a period of 7.37 ± 3.00 months (range, 2-13 months). Thirty-five eyes (56.5%) had an increase in IOP during the follow-up period. Thirty-one patients had transient ocular hypertension requiring topical treatment during the immediate postoperative period (one month). Only 1 eye (2.9%) required filtrating drainage surgery for IOP control. No eyes developed optic neuropathy secondary to IOP elevation. CONCLUSION: Pars plana vitrectomy with SO injection seems to be a safe and efficient surgical approach in the treatment of primary uncomplicated rhegmatogenous retinal detachment in patients living in high altitude (>1,000 m). Also, PPV and SO injection are associated with good anatomical and functional outcomes in our series. Reattachment rates are high, and rates of proliferative vitreoretinopathy are low. Cataract formation and elevated IOP represent frequent but successfully controlled complications.

Rate of corneal collagen crosslinking redo in private practice: risk factors and safety.

Objective. To report the rate of progression of keratectasia after primary crosslinking (CXL) and evaluate the safety and efficiency of CXL redo. Materials and Methods. We conducted a retrospective analysis of the patients who underwent CXL between 2010 and 2013 at the Beirut Eye Specialist Hospital, Lebanon. Progression of keratectasia was based on the presence of an increase in maximum keratometry of 1.00 D, a change in the map difference between two consecutive topographies of 1.00 D, a deterioration of visual acuity, or any change in the refraction. Primary and redo CXL were done using the same protocol. Results. Among the 221 eyes of 130 patients who underwent CXL, 7 eyes (3.17%) of five patients met the criteria of progression. All patients reported a history of allergic conjunctivitis and eye rubbing and progressed within 9 to 48 months. No complications were noted and all patients were stable 1 year after CXL redo. Conclusion. Allergic conjunctivitis and eye rubbing were the only risk factors associated with keratoconus progression after CXL. A close followup is thus mandatory, even years after the procedure. CXL redo seems to be a safe and efficient technique to halt the progression after a primary CXL.

Static cyclotorsion measurements using the Schwind Amaris laser.

PURPOSE: To assess the reliability and reproducibility of static cyclotorsion correction (SCC) measurements made using the Schwind Amaris Excimer laser in patients undergoing LASIK or PRK, and compare the outcomes of treating astigmatism with and without SCC. METHODS: Eighty eyes of 40 patients were included in this study. All eyes underwent 2 or 3 sets of five measurements: before and after speculum placement, and after flap-lift (in LASIK cases). We assessed the reproducibility, accuracy, and the percentage of "no catch" measurements. The astigmatism was calculated pre-and 3-months-postoperatively by vector analysis. RESULTS: The mean age of the patients was 23.67 ・} 4.19 years. Preoperative spherical equivalent and astigmatism were -2.56 ・} 2.86 D and +1.36 ・} 0.98 D, respectively. The mean measurement time was 15.1 seconds per measurement. The percentages of "no catch" were: 63.8%, 14.9%, and 26.9%; pre-speculum, post-speculum, and post flap-lift, respectively. Cyclotorsion of ≥}2° was seen in 41.25% and 66% of the cases before and after the flap-lift, respectively. Significant cyclotorsion (≥}5°) was seen in 12.50% and 18% of the eyes pre and post flap-lift. The mean astigmatism dropped from +1.53 D@1° to +0.34D@3° when SCC was used and from +1.86D@1° to +0.23D@7° when SCC was not used. No statistical difference was noticed between the groups (p>0.05) in the postoperative residual astigmatism. A postoperative astigmatism of ≥ D was seen in 10% and 20% of eyes with and without SCC, respectively (p<0.01). CONCLUSION: Although not always feasible, the SCC measurement is a simple and useful tool. Postoperative astigmatism showed less variability when SCC was used.

Spontaneous simultaneous bilateral malignant glaucoma of a patient with no antecedent history of medical or surgical eye diseases.

PURPOSE: Malignant glaucoma, or aqueous misdirection syndrome, is a condition characterized by sudden intraocular pressure (IOP) elevation, and it is usually unilateral and induced by ocular surgical intervention or by medical therapy. Here, we report a case of simultaneous bilateral malignant glaucoma in a young patient with no history of any ocular diseases. CASE REPORT: A case of a 24-year-old female with no apparent previous history of ocular medical or surgical conditions was referred to our hospital because of recent bilateral IOP elevation associated with a severe drop in vision and shallow anterior chamber with no posterior segment anomalies detected by ocular ultrasound in both eyes. Yttrium aluminum garnet (YAG) laser iridotomy dropped the IOP only temporarily and the patient received topical atropine treatment with combined trabeculectomy and anterior vitrectomy. RESULTS: In this case, the patient had a typical presentation of bilateral malignant glaucoma and her IOP dropped only temporarily following laser iridotomy to rise again shortly thereafter. Also, deepening of the anterior chamber and IOP decrease after topical atropine was very supportive of the diagnosis of malignant glaucoma. Successful management with trabeculectomy and limited vitrectomy also affirmed the diagnosis of malignant glaucoma. CONCLUSION: This is a very rare case of bilateral malignant glaucoma in a young adult without any prior eye conditions; only one similar case has been reported in the literature. We propose our own theory regarding this simultaneous occurrence of the pathology based on previously published studies about the presence of communication between the two eyes along the cerebrospinal fluid pathways.

Static cyclotorsion measurements using the Schwind Amaris laser / Medições da ciclotorção estática usando o laser Schwind Amaris

Purpose: To assess the reliability and reproducibility of static cyclotorsion correction (SCC) measurements made using the Schwind Amaris Excimer laser in patients undergoing LASIK or PRK, and compare the outcomes of treating astigmatism with and without SCC. Methods: Eighty eyes of 40 patients were included in this study. All eyes underwent 2 or 3 sets of five measurements: before and after speculum placement, and after flap-lift (in LASIK cases). We assessed the reproducibility, accuracy, and the percentage of "no catch" measurements. The astigmatism was calculated pre-and 3-months-postoperatively by vector analysis. Results: The mean age of the patients was 23.67 ± 4.19 years. Preoperative spherical equivalent and astigmatism were -2.56 ± 2.86 D and +1.36 ± 0.98 D, respectively. The mean measurement time was 15.1 seconds per measurement. The percentages of "no catch" were: 63.8%, 14.9%, and 26.9%; pre-speculum, post-speculum, and post flap-lift, respectively. Cyclotorsion of ≥±2º was seen in 41.25% and 66% of the cases before and after the flap-lift, respectively. Significant cyclotorsion (≥±5º) was seen in 12.50% and 18% of the eyes pre and post flap-lift. The mean astigmatism dropped from +1.53 D@1º to +0.34D@3º when SCC was used and from +1.86D@1º to +0.23D@7º when SCC was not used. No statistical difference was noticed between the groups (p>0.05) in the postoperative residual astigmatism. A postoperative astigmatism of ≥1 D was seen in 10% and 20% of eyes with and without SCC, respectively (p<0.01). Conclusion: Although not always feasible, the SCC measurement is a simple and useful tool. Postoperative astigmatism showed less variability when SCC was used. .

Objetivo: Avaliar a confiabilidade e reprodutibilidade da correção da medida de ciclotorção estática (SCC), realizada com o excimer laser Schwind Amaris em pacientes submetidos a LASIK ou PRK, e comparar os resultados do tratamento de astigmatismo com e sem SCC. Método: Oitenta olhos (40 pacientes). Todos os olhos foram submetidos a 2 ou 3 séries de 5 medições: antes e após a colocação do espéculo, e depois do levantamento do flap (nos casos de LASIK). Foram avaliadas a reprodutibilidade, a precisão e a porcentagem de medições "não obtidas". O astigmatismo foi avaliado no pré-operatório e aos 3 meses de pós-operatório, por meio de análise vetorial. Resultados: A idade foi 23,67 ± 4,19 anos. O equivalente esférico e o astigmatismo pré-operatórios foram -2,56 ± 2,86 D, e 1,36 ± 0,98 D, respectivamente. O tempo de medição médio foi 15,1 segundos por medição; as porcentagens de medidas "não obtidas" foram: 63,8%, 14,9% e 26,9%; pré, pós-espéculo, e pós-levantamento do flap, respectivamente. Ciclotorção ≥±2º foi observada em 41,25% e 66 % dos casos pré e pós-levantamento do flap. Ciclotorção significativa (≥±5º) foi observada em 12,50% e 18% pré e pós-levantamento do flap. A média do astigmatismo diminuiu de 1,53D @ 1º para 0,34D @ 3º quando SCC foi usado e de 1,86D @ 1º a 0,23D @7º quando SCC não foi usado. O astigmatismo residual pós-operatório não foi estatisticamente diferente entre os grupos (p>0,05). O astigmatismo pós-operatório ≥1D foi observado em 10% e 20 % dos olhos com e sem SCC, respectivamente (p<0,01). Conclusão: A medição do SCC é fácil e útil, apesar de nem sempre ...

Azithromycin 1.5% ophthalmic solution: efficacy and treatment modalities in chronic blepharitis.

PURPOSE: To assess the efficacy of topical 1.5% azithromycin in the treatment of moderate to severe chronic blepharitis and to compare the efficacy of two different treatment modalities. METHODS: A randomized clinical trial included 67 patients with chronic anterior and/or posterior blepharitis, followed-up for 3 months. Signs and symptoms were graded according to severity. Patients were randomized into two groups: 33 patients in group I and 34 patients in group II. Group I patients were treated with topical 1.5% azithromycin twice a day for three days, and Group II patients were treated with topical 1.5% azithromycin twice a day for three days then at bedtime for the rest of the month. All patients were instructed to apply warm compresses and an eye-friendly soap twice daily. RESULTS: Patients in both groups tolerated the treatment with minimal irritation. A significant improvement in signs and symptoms was noted at the one week follow-up visit. Group II showed a more pronounced and longer-lasting improvement that persisted after three months of follow-up. CONCLUSION: Topical 1.5% azithromycin ophthalmic solution is an effective treatment option for chronic blepharitis. In moderate to severe blepharitis, a one month treatment is safe and shows better improvement than the three-day protocol with no significant relapse until three months of follow-up.

Azithromycin 1.5% ophthalmic solution: efficacy and treatment modalities in chronic blepharitis / Solução oftálmica de azitromicina 1,5%: eficácia e modalidades de tratamento em blefarite crônica

PURPOSE: To assess the efficacy of topical 1.5% azithromycin in the treatment of moderate to severe chronic blepharitis and to compare the efficacy of two different treatment modalities. METHODS: A randomized clinical trial included 67 patients with chronic anterior and/or posterior blepharitis, followed-up for 3 months. Signs and symptoms were graded according to severity. Patients were randomized into two groups: 33 patients in group I and 34 patients in group II. Group I patients were treated with topical 1.5% azithromycin twice a day for three days, and Group II patients were treated with topical 1.5% azithromycin twice a day for three days then at bedtime for the rest of the month. All patients were instructed to apply warm compresses and an eye-friendly soap twice daily. RESULTS: Patients in both groups tolerated the treatment with minimal irritation. A significant improvement in signs and symptoms was noted at the one week follow-up visit. Group II showed a more pronounced and longer-lasting improvement that persisted after three months of follow-up. CONCLUSION: Topical 1.5% azithromycin ophthalmic solution is an effective treatment option for chronic blepharitis. In moderate to severe blepharitis, a one month treatment is safe and shows better improvement than the three-day protocol with no significant relapse until three months of follow-up.

OBJETIVO: Avaliar a eficácia do uso tópico de azitromicina 1,5% no tratamento de blefarite crônica moderada a grave, comparando a eficácia de duas diferentes modalidades de tratamento. MÉTODOS: Um ensaio clínico randomizado incluiu 67 pacientes com blefarite anterior e/ou posterior crônica, acompanhados por três meses. Os sinais e sintomas foram classificados de acordo com a gravidade. Os pacientes foram randomizados em dois grupos: 33 pacientes no grupo I e 34 pacientes no grupo II. Os pacientes do grupo I foram tratados com azitromicina tópica 1,5% duas vezes ao dia durante três dias, e os pacientes do grupo II foram tratados com azitromicina tópica 1,5% duas vezes ao dia durante três dias e, em seguida, ao deitar, durante o resto do mês. Todos os pacientes foram instruídos a aplicarem compressas quentes e higiene palpebral duas vezes ao dia. RESULTADOS: Os pacientes em ambos os grupos toleraram o tratamento com irritação mínima. Melhora significativa dos sinais e sintomas foi observada na visita de uma semana de acompanhamento. Grupo II mostrou uma melhora mais acentuada e mais duradoura que persistiu após três meses de acompanhamento. CONCLUSÕES: A solução de azitromicina oftálmica tópica 1,5% é uma opção eficaz de tratamento para a blefarite crônica. Em blefarite moderada a grave, o tratamento de um mês é seguro e demonstrou melhora acentuada em relação ao protocolo de três dias, sem recidiva significante até três meses de acompanhamento.